Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 11Stomach Neoplasms 5Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Gastric Adenocarcinoma 2Cholangiocarcinoma 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Osteosarcoma 1Neuroblastoma 1Malignant Neoplasms of Digestive Organs 1Liver Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Stromal Tumors 1Fludzoparib" and Anti-angiogenic 1Colonic Neoplasms 1Cirrhosis, Familial, with Pulmonary Hypertension 1Advanced Primary Liver Cancer 1Advanced Biliary Tract Carcinoma 1Adebrelimab 1

Interventions

camrelizumab 1apatinib 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Primary Liver Cancer × apatinib × 1 year × Clear all
NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
157 enrolled 17 charts
Gastrointestinal

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡